玻璃体腔注射雷珠单抗治疗点状内层脉络膜病变并发的脉络膜新生血管  

Intravitreal ranibizumab treatment for choroidal neovascularization secondary to punctate inner choroidopathy

作　　者：廖丹 许立帅[1] 戴乐[1] 杨桢[1] 杨小丽[1] LIAO Dan;XU Li-shuai;DAI Le;YANG Zhen;YANG Xiao-li(Department of Ophthalmology,Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,Sichuan,China)

机构地区：[1]川北医学院附属医院眼科,四川南充637000

出　　处：《川北医学院学报》2019年第1期28-31,共4页Journal of North Sichuan Medical College

基　　金：四川省教育厅重点项目(17ZA0171)

摘　　要：目的:观察玻璃体腔注射雷珠单抗治疗点状内层脉络膜病变(punctate inner choroidopathy,PIC)并发的脉络膜新生血管(choriodal neovascularization,CNV)的疗效。方法:本实验回顾性分析了8只接受玻璃体腔注射雷珠单抗治疗PIC并发CNV的患眼。所有患者都接受过一系列广泛的眼部检查,包括最佳矫正视力(BCVA)、裂隙灯检查、眼压、眼底检查、SD-OCT、FFA、ICGA。在第1次治疗后,每例患者至少完成6个月的随访检查。评估内容包括BCVA及黄斑中心凹视网膜厚度(central macular thickness,CMT)。结果:87.5%的患眼能维持原有视力或者视力改善,平均提高1.5行。患者的BCVA由治疗前的(0.39±0.11)提高到(0.22±0.19),差异有统计学意义(P=0.028)。患者治疗前CMT平均(275.50±53.53)μm,接受玻璃体腔雷珠单抗注入术后CMT平均(213.63±22.86)μm。患者接受治疗玻璃体腔雷珠单抗注入术后与治疗前对比,CMT值显著下降,差异有统计学意义(P=0.017)。结论:玻璃体腔注射雷珠单抗治疗PIC并发的CNV,疗效安全肯定。Objective:To assess the outcome of patients with choroidal neovascularization(CNV) secondary to punctate inner choroidopathy(PIC) receiving intravitreal ranibizumab injections.Methods:8 eyes with PIC complicated with CNV received intravitreal injection of ranibizumab were retrospectively analyzed.A comprehensive ocular examination was done before and after treatment which included an assessment of the best-corrected distance visual acuity(BCVA),slit-lamp examination,intraocular pressure,fundoscopy,spectral domain optical coherence tomography(SD-OCT),fundus fluorescein angiography(FFA) and indocyanine green angiography(ICGA).Each patient was followed up at least 6 months after the first treatment.BCVA and central macular thickness(CMT) on SD-OCT were used to measure the response to treatment.Results:87.5 % of the eyes were able to maintain the original vision or improved vision,with a mean visual improvement of 1.5 lines.The BCVA of patients increased from(0.39 +0.11) before treatment to(0.22+0.19) after treatment,and the difference was significant(P=0.028).The mean CMT of patients was significantly reduced from 275.50±53.53 μm before treatment to 213.63±22.86 μm after treatment.Compared with before treatment,CMT value decreased significantly,the difference was statistically significant(P=0.017).Conclusion:Intravitreal ranibizumab therapy seems to be safe and effective for PIC-related CNV.

关 键 词：点状内层脉络膜病变 脉络膜新生血管 雷珠单抗 

分 类 号：R773.4[医药卫生—眼科]